

IN THE CLAIMS:

Q 3. (Amended) The isolated and/or recombinant nucleotide sequence of claim 2 wherein said cell cycle dependency is a G2/M cell cycle dependency.

C 1
Q 2 11. (Amended) A chimeric gene comprising:
a) the isolated and/or recombinant nucleotide sequence of claim 3, and
b) one or more control sequences operably linked to said isolated and/or recombinant nucleotide sequence.

Q 3 12. (Amended) A vector comprising the isolated and/or recombinant nucleic acid molecule of claim 3.

Q 4 C 8 14. (Amended) A eukaryotic host cell comprising the nucleic acid molecule of claim 3.

Q 5 C 9 17. (Amended) A method of inducing a cell cycle dependent initiation of translation in a eukaryotic cell, said method comprising introducing the isolated and/or recombinant nucleotide sequence of claim 3 into said eukaryotic cell.

Q 6 C 9 20. (Amended) A pharmaceutical composition for treating and/or preventing a disease in a subject by gene therapy, said pharmaceutical composition comprising:
the isolated and/or recombinant nucleotide sequence of claim 3 together with means for delivering said isolated and/or recombinant nucleotide sequence to the subject.